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Edinburgh, UKAbstract—Dopamine (DA) releasing midbrain neurons are
essential for multiple brain functions, such as voluntary
movement, working memory, emotion and cognition. DA
midbrain neurons within the substantia nigra (SN) and the
ventral tegmental area (VTA) exhibit a variety of distinct axo-
nal projections and cellular properties, and are diﬀerentially
aﬀected in diseases like schizophrenia, attention deﬁcit
hyperactivity disorder, and Parkinson’s disease (PD). Apart
from having diverse functions in health and disease states,
DA midbrain neurons display distinct electrical activity
patterns, crucial for DA release. These activity patterns are
generated and modulated by speciﬁc sets of ion channels.
Recently, two ion channels have been identiﬁed, not only
contributing to these activity patterns and to functional
properties of DA midbrain neurons, but also seem to render
SN DA neurons particularly vulnerable to degeneration in
PD and its animal models: L-type calcium channels (LTCCs)
and ATP-sensitive potassium channels (K-ATPs). In this
review, we focus on the emerging physiological and
pathophysiological roles of these two ion channels (and their
complex interplay with other ion channels), particularly in
highly vulnerable SN DA neurons, as selective degeneration
of these neurons causes the major motor symptoms of PD.
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THE DOPAMINERGIC MIDBRAIN SYSTEM
Dopamine (DA) releasing midbrain neurons are crucial for
fundamental and complex brain functions, such as
voluntary movement and goal-directed behavior, as well
as cognition, emotion, reward, motivation, working
memory, associative learning and decision making
(Grace et al., 2007; Redgrave et al., 2010; Schultz,
2010a; Gerfen and Surmeier, 2011; Salimpoor et al.,
2011; D’Ardenne et al., 2012; Chowdhury et al., 2013).
Accordingly, dysfunctions of the DA midbrain system
are associated with neurological and psychiatric dis-
eases, such as schizophrenia, addiction, attention deﬁcit
hyperactivity disorder (ADHD) and Parkinson’s disease
(PD), the second most common neurodegenerative dis-
ease (Braak et al., 2004; Bjorklund and Dunnett, 2007;
Dagher and Robbins, 2009; Stuber et al., 2010;
Shulman et al., 2011; Bari and Robbins, 2013; Russo
and Nestler, 2013; Sulzer and Surmeier, 2013; Brisch
et al., 2014). The majority of DA midbrain neurons are
located in two overlapping nuclei, the substantia nigra
(SN, A9) and the ventral tegmental area (VTA, A10)
(Schultz, 2010b). These neurons have widespread axonal
projections to subcortical and cortical target areas, and
display diverse electrophysiological properties in vitroons.org/licenses/by-nc-nd/3.0/).
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patterns (Liss & Roeper, 2010; Roeper, 2013). With
respect to their distinct projections, electrophysiological
properties and gene expression proﬁles, at least ﬁve
subpopulations of SN DA and VTA DA neurons can be
deﬁned (reviewed in (Margolis et al., 2010; Ungless and
Grace, 2012; Roeper, 2013)), which are diﬀerentially
aﬀected in diseases of the DA midbrain system
(Wichmann et al., 2011). So-called mesostriatal SN DA
neurons, projecting to the dorsal striatum, are particularly
important for voluntary movement control as well as for
motor learning, habit formation, goal-directed action
selection and exploration (Chase et al., 2004;
Balleine and O’Doherty, 2009; Jin and Costa, 2010;
Redgrave et al., 2010; Costa, 2011; Schiemann et al.,
2012; Everitt and Robbins, 2013) while neighboring
VTA DA neurons, with axonal projections to e.g. limbic
and cortical areas, play central roles in cognition,
motivation, addiction, reward and aversive behavior
(Margolis et al., 2010; Stuber et al., 2010; Bourdy
and Barrot, 2012; Lammel et al., 2012; Ungless and
Grace, 2012; Luscher, 2013; Roeper, 2013; Lammel,
2014).
In this review, we will focus on the physiology and
pathophysiology of mesostriatal SN DA neurons. We will
discuss the role of ion channels for deﬁning and
modulating SN DA activity patterns and for rendering
these neurons particularly vulnerable to degeneration in
PD. For a general introduction into ion channels,
membrane potential recordings and patch-clamp
techniques, we refer to respective excellent textbooks
(Hille, 2001; Sakmann & Neher, 2010; Zheng &
Trudeau, 2015).MOLECULAR PATHOLOGY OF THE DA
MIDBRAIN SYSTEM IN PD
In human patients, the typical motor symptoms of PD
(rigor, tremor, bradykinesia/akinesia) occur late within
the neurodegenerative process, when a signiﬁcant
number of nigrostriatal axons (an early feature in PD)
as well as SN DA neuron somata are already lost
(Collier et al., 2011; Shulman et al., 2011; Burke and
O’Malley, 2013; Surmeier and Schumacker, 2013). Con-
sequently, there is still no cure or causal neuroprotec-
tive therapy available, but current established PD
therapies attempt to compensate the progressive loss
of striatal DA by administering its precursor L-DOPA,
and/or DA D2-receptor agonists (Collier et al., 2011;
Gazewood et al., 2013; Olanow and Schapira, 2013).
Invasive deep brain stimulation (DBS) approaches
reduce tremor and improve motor symptoms of PD
and of its DA-mimetic therapy (dopaminergic therapy)
(Deuschl and Agid, 2013). Understanding the molecular
mechanisms of function and signaling of SN DA neu-
rons in health and disease is the prerequisite for the
development of novel, neuroprotective and/or curative
PD therapies that aim to slow down or stop theprogressive loss of DA neurons and their striatonigral
axons.
Important in this context is that DA midbrain neurons
are not equally aﬀected by the degenerative process in
PD, with SN DA neurons being particularly vulnerable
to PD-trigger factors (as speciﬁed below), compared to
more resistant neighboring VTA DA neurons (Bjorklund
and Dunnett, 2007; Schultz, 2010b). In addition, SN
DA neurons expressing the calcium-binding protein cal-
bindin (CBd28k), located mainly in the dorsal tier of the
SN, are less susceptible to PD-triggers and degenera-
tion, whereas calbindin-immunonegative ventral tier SN
DA neurons are most vulnerable (Fearnley and Lees,
1991; Damier et al., 1999; Collier et al., 2013). The
molecular causes for this so-called selective vulnerability
of DA midbrain neurons to PD-triggers and to degenera-
tion are still unclear (Surmeier and Schumacker, 2013).
However, similar degeneration patterns are present in
respective animal models of PD (Collier et al., 2013),
and seem to be caused by speciﬁc intrinsic properties
of highly vulnerable SN DA neurons (Surmeier et al.,
2012). Consequently, a similar selective and progressive
loss of SN DA neurons already occurs during normal
aging – although the pattern of cell loss during aging
and in PD is not identical (Fearnley and Lees, 1991;
Damier et al., 1999; Collier et al., 2011). Accordingly,
age is the largest risk factor for the development of PD
(Jagust, 2013). In addition, a variety of other PD-trigger
factors have been identiﬁed – environmental factors
(e.g. mitochondrial toxins such as rotenone, which is still
widely used in bulk amounts for river treatment to ﬁght
ﬁsh parasites (Finlayson et al., 2014)) as well as genetic
factors (e.g. PARK-genes), as summarized in detail in
excellent reviews (Hirsch and Hunot, 2009; Hardy,
2010; Alves da Costa and Checler, 2011; Collier et al.,
2011; Gasser et al., 2011; Surmeier et al., 2012;
Moskvina et al., 2013; Ramanan and Saykin, 2013;
Singleton et al., 2013; Sulzer and Surmeier, 2013). In
essence, activity-related cellular Ca2+ load, mitochon-
drial DNA deletions and mitochondrial dysfunction, as
well as oxidative and metabolic stress are particularly
important trigger factors for PD (Bender et al., 2006;
Guzman et al., 2010; Alves da Costa and Checler,
2011; Collier et al., 2011; Shulman et al., 2011; Watfa
et al., 2011; Coskun et al., 2012; Surmeier and
Schumacker, 2013; Checler and Alves da Costa, 2014;
Parlato and Liss, 2014; Phillipson, 2014). Furthermore,
orchestrated ion channel activity tightly controls electrical
activity of SN DA neurons, and is crucial for both, their
age-dependent physiological functions and response to
pathophysiological conditions (Liss & Roeper, 2010;
Surmeier et al., 2012). In particular, voltage-gated L-type
Ca2+ channels (LTCCs), most likely the Cav1.3 subtype,
as well as metabolically gated, ATP-sensitive K+
(K-ATP) channels in SN DA neurons, not only modulate
the distinct ﬁring patterns of these neurons, but have
recently also been shown to contribute to their
progressive loss and to PD pathology (Liss et al.,
2005; Chan et al., 2007; Mosharov et al., 2009;
Fig. 1. Distinct activity patterns and underlying ion channel expression in substantia nigra dopamine (SN DA) neurons. (A). Typical in vivo and
in vitro activity patterns of SN DA neurons from adult mice. Left: In vivo extracellular single-unit recordings from identiﬁed SN DA neurons recorded
in anesthetized mice, displaying tonic single-spike ﬁring (top) and phasic burst ﬁring (bottom); scale bars = 0.5 s, 0.2 mV. Multi-ﬂuorescence,
confocal microscopy image of a neurobiotin-labeled (green), tyrosine hydroxylase (blue) immunopositive SN DA neuron after in vivo recording and
juxtacellular labeling. Scale bar = 25 lm. Right: vital SN DA neuron in an acute coronal mouse midbrain slice, with the patch-pipette approaching
the cell. Scale bar = 15 lm. Perforated-patch current-clamp recordings of an SN DA neuron in vitro, ﬁring in pacemaker mode (top) and of a
hyperpolarized SN DA neuron showing no spontaneous activity (bottom). Dotted lines at 40 mV; scale bars = 0.5 s, 25 mV. (B) Schematic
illustration of distinct ion channels in SN DA neurons that generate or modulate their activity patterns in vivo and in vitro, and are associated with
oscillating Ca2+ levels and elevated metabolic mitochondrial stress levels (see text for details). Note that only a selection of ion channels and
mechanisms is depicted. The A-type potassium channel b-subunit KChip3, also known as transcription factor DREAM, can regulate SN DA gene
expression by Ca2+-dependent binding to nuclear DRE elements (similar as Ca2+ dependent CREB/CRE regulation of gene expression).
Abbreviations: VGCC: voltage-gated calcium channels; LTCC (Cav1.3): Cav1.3 L-type voltage-gated calcium channel; Kv4.3/KChip3: A-type
voltage-gated potassium channel; TTCC: T-type voltage-gated calcium channel; SK3: small conductance, calcium-sensitive potassium channel;
Nav: tetrodotoxin (TTX)-sensitive voltage-gated sodium channel, TRP: transient receptor potential channel; ENaC: epithelia sodium channel; HCN:
hyperpolarization and cyclic nucleotide-gated cation channel; NMDA-R; N-methyl-D-aspartate glutamate receptor; K-ATP: ATP-sensitive potassium
channel; Kir6.2: inwardly rectifying potassium channel; SUR1: sulfonylurea receptor; D2-AR: dopamine D2-autoreceptor; GIRK2: G-protein-coupled
inwardly rectifying potassium channel; NCS-1: neuronal calcium sensor 1; DREAM: DRE antagonist modulator; CREB: cAMP response element-
binding protein; ER: endoplasmic reticulum; mCU: mitochondrial calcium uniporter; ROS: reactive oxygen species; mNOS: mitochondrial nitric oxide
synthase, NO: nitric oxide; UCP: uncoupling protein; DJ-1: Parkinson’s disease protein 7 (PARK7); SOD: superoxide-dismutase.
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et al., 2012; Surmeier et al., 2012; Dragicevic et al.,
2014). There is also emerging evidence for other ion
channels, like voltage-gated T-type Ca2+ channels
(TTCCs), particularly in the STN (Zhang et al., 2013;
Yang et al., 2014), and Ca2+-sensitive, voltage-gated
A-type K+ channels (Liss et al., 2001; Turner and
Zamponi, 2014) that contribute – in interplay with LTCCs
and K-ATP channels – to basal ganglia dysfunction,
selective SN DA pathophysiology and PD, as we sum-
marize in this review.DISTINCT ACTIVITY PATTERNS OF SN DA
NEURONS – ROLE OF ION CHANNELS
In order to fully comprehend the crucial roles of ion
channels for SN DA function in health and disease, one
needs to understand their fundamental role for the
generation of neuronal electrical activity patterns. SN
DA neurons are spontaneously active (Grace and
Bunney, 1984a,b), and their tonic action potential ﬁring
is crucial for DA release from striatal axon terminals as
well as from soma and dendrites of SN DA neurons
(Rice et al., 2011). In vivo, within the intact basal ganglia
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of ﬁring patterns (Fig. 1A, left): tonic irregular single-spike
activity in the frequency range of 1–10 Hz (Grace and
Bunney, 1984b), or phasic burst activity at higher frequen-
cies (13–20 Hz in anesthetized animals, or up to 80 Hz
in awake animals or humans) (Grace and Bunney,
1984a; Bayer et al., 2007; Tepper and Lee, 2007; Ishida
et al., 2009; Lee & Tepper, 2009; Zaghloul et al., 2009;
Drion et al., 2010; Schiemann et al., 2012). The onset
of burst activity is classically deﬁned as two consecutive
spikes with an interspike interval (ISI) <80 ms, and a
burst lasts until an ISI exceeds 160 ms (80/160-ms crite-
rion; (Grace and Bunney, 1984a)). In vitro (Fig. 1A, right),
in synaptic isolation, SN DA neurons predominantly
display an intrinsically generated, regular, so-called
pacemaker activity, with relatively low frequency
(0.5–3 Hz) (Bean, 2007a; Ford and Williams, 2008;
Lammel et al., 2008; Margolis et al., 2010; Drion et al.,
2011; Ungless and Grace, 2012; Branch et al., 2014).
Tonic irregular or pacemaker SN DA neuron ﬁring is asso-
ciated with tonic baseline DA release (Rice et al., 2011),
thereby enabling basic motor activity (Surmeier and
Schumacker, 2013). In contrast, burst activity of SN DA
neurons causes phasic supralinearly increased DA
release in response to novel, unexpected or salient
events, and encodes so-called ‘‘Go’’ signals facilitating
movement initiation and motor learning and reward
prediction (Chase et al., 2004; Schultz, 2007; Bromberg-
Martin et al., 2010; Jin and Costa, 2010; Costa, 2011;
Morikawa and Paladini, 2011). Interestingly, in awake
PD patients, SN DA neurons seem to display an about
twofold increase in burst activity, while their mean ﬁring
frequency is not elevated (Zaghloul et al., 2009;
Schiemann et al., 2012). This increase in SN DA burst
activity could reﬂect a homeostatic compensation for the
progressive loss of SN DA neurons and DA release
capacity in the course of PD.
The complex and age-dependent interplay of how
distinct types of ion channels and receptors shape these
activity patterns of SN DA neurons is illustrated in
Fig. 1B, and reviewed in detail elsewhere (Chan et al.,
2007; Khaliq and Bean, 2010; Liss & Roeper, 2010;
Margolis et al., 2010; Surmeier et al., 2012; Ungless
and Grace, 2012; Dufour et al., 2014). Here, we focus
on the roles of LTCCs and K-ATP channels in SN DA
neurons for their physiological functions and involvement
in PD pathology. We will oﬀer an explanation how these
two ion channels can cause and transduce PD-trigger
factors, like activity-dependent and Ca2+-related meta-
bolic stress, and thus deﬁne SN DA neurons particularly
vulnerable to degeneration in PD.FUNCTIONAL ROLES OF LTCCS IN SN DA
NEURONS
Role of LTCCs for SN DA pacemaker activity?
Brain LTCCs contain pore-forming Cav1.2 or Cav1.3
subunits in complex with an accessory b and a2-d
subunit (Catterall et al., 2005; Dolphin, 2006). Both iso-
forms are also expressed in SN DA neurons (Olsonet al., 2005; Chan et al., 2007; Dragicevic et al., 2014).
LTCCs are active during SN DA spike activity
(Lipscombe et al., 2004), and they generate activity-asso-
ciated, calcium-mediated slow oscillatory potentials,
SOPs (Puopolo et al., 2007; Guzman et al., 2009;
Putzier et al., 2009). However, LTCCs also substantially
contribute to the oscillatory calcium inﬂux during the
interspike interval (ISI) between two action potentials
(Bean, 2007a; Bean, 2007b). This is most likely due to
Cav1.3 channel activity, which can activate at negative
membrane potentials (Koschak et al., 2001; Putzier
et al., 2009; Striessnig et al., 2014). Both LTCCs are
pharmacologically blocked by dihydropyridines (DHPs,
channel inhibitors that prevent calcium permeation
through the channel pore (Striessnig et al., 1998), like
isradipine (Snutch et al., 2001; Catterall et al., 2005;
Striessnig et al., 2006; Adams and Snutch, 2007;
Surmeier et al., 2010; Coca et al., 2013)). Block of LTCCs
(with 5 lM isradipine or 1 lM nimodipine) in SN DA neu-
rons can abolish the SOPs in young adult mice (PN21-32)
in vitro, without aﬀecting their pacemaker activity
(Puopolo et al., 2007; Guzman et al., 2009). A causal con-
tribution of LTCCs to generation or modulation of pace-
maker activity in mature SN DA neurons is still
controversial. More precisely, a postnatal age-dependent
switch from HCN (hyperpolarization-activated cyclic
nucleotide gated) cation channel-driven pacemaking in
juvenile mouse SN DA neurons to Cav1.3 LTCC-driven
pacemaking in adult SN DA neurons has been suggested.
Due to the metabolically more challenging Ca2+ load, the
latter pacemaker mode would render SN DA neurons
more vulnerable to PD-triggers. However, this ﬁnding is
highly disputed and seems to depend on used DHP con-
centrations and recording conditions of individual labora-
tories (Chan et al., 2007; Puopolo et al., 2007; Bean,
2007b; Guzman et al., 2009; Putzier et al., 2009; Liss &
Roeper, 2010; Drion et al., 2011; Branch et al., 2014).
Under our experimental conditions (in vitro brain slices
of PN13 and PN90 C57BL/6 male mice; acute LTCC
block by 300 nM isradipine, or chronic Cav1.3 LTCCs deﬁ-
ciency in Cav1.3 KO mice), LTCCs were not required for
SN DA pacemaker activity – neither in juvenile nor adult
mice (Dragicevic et al., 2014). However, we and others
observed that LTCC activity seems to enhance the
robustness of SN DA neurons to sustain spiking, e.g. in
response to altered extrinsic inputs (Guzman et al.,
2009). Of great pathophysiological relevance is the ﬁnd-
ing by Surmeier and colleagues that during pacemaking
LTCCs participate in the generation of dendritic Ca2+
oscillations. The LTCC contribution to this Ca2+ tran-
sients increases with distance from the soma and is
selective for SN DA but not VTA DA neurons of
PN21–30 mice (Guzman et al., 2010; Dryanovski et al.,
2013). These isradipine-sensitive (5 lM) Ca2+
oscillations cause a ﬂickering of the mitochondrial mem-
brane potential in SN DA but not VTA DA neurons, and
are generating respective oscillating high levels of oxida-
tive stress (Mosharov et al., 2009; Guzman et al., 2010;
Surmeier et al., 2011). In response to this LTCC-induced
oscillating oxidative stress, presumably caused by Cav1.3
channels, SN DA neurons engage defense mechanisms,
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(ROS). These include intracellular endoplasmic reticulum
(ER) and mitochondrial Ca2+ buﬀering, transient mild
mitochondrial uncoupling (by uncoupling proteins, UCPs),
and antioxidative mechanisms mediated by PARK-gene
function, e.g. DJ-1 (PARK7) (Guzman et al., 2010;
Sanchez-Padilla et al., 2014).
In summary, Cav1.3 and Cav1.2 LTCCs are active
selectively in SN DA neurons during pacemaking, and
they cause an oscillating calcium burden inducing
mitochondrial stress. This renders SN DA neurons
particularly vulnerable to degeneration by known
PD-triggers (e.g. PARK-gene mutations, toxins).
However, as LTCC function is not essential for SN DA
pacemaker activity (but seems to contribute to its
robustness) the question remains, why SN DA neurons
need LTCCs in contrast to VTA DA neurons, and what
could be their physiological role.
LTCCs as homeostatic gatekeepers: SN DA activity
control via D2-autoreceptor modulation
Recently, we identiﬁed a novel physiological role of
Cav1.3 LTCCs selectively in SN DA neurons for
modulating somatodendritic D2-autoreceptor (D2-AR)
function via the neuronal calcium sensor 1 (NCS-1)
(Dragicevic et al., 2014). G-protein-coupled somatoden-
dritic D2-ARs reduce activity and excitability of DA neu-
rons, in response to local, somatodendritically released
DA acting in a negative feedback (Ford et al., 2010;
Ford, 2014) through activation of G-protein-coupled,
inwardly rectifying potassium channels (GIRK2 = Kir3.2)
(Luscher and Slesinger, 2010). Compared to VTA DA
neurons, SN DA neurons from adult mice display promi-
nent, non-desensitizing D2-AR responses (Lammel
et al., 2008; Margolis et al., 2010). This response under-
goes postnatal maturation: in contrast to adult SN DA
neurons, D2-AR responses in PN13 SN DA neurons dis-
play pronounced desensitization (Dragicevic et al., 2014).
Surprisingly, this maturation of D2-AR responses is
absent in PARK7 KO (DJ-1) or PARK8 transgenic
(LRRK2-R1441C) mice, where adult SN DA neurons still
display juvenile-like desensitizing D2-AR responses
(Goldberg et al., 2005; Tong et al., 2009; Tong and
Shen, 2012). In juvenile SN DA neurons, transient
high-dopamine states, induced by a single in vivo admin-
istration of L-DOPA or cocaine (an inhibitor of plasma
membrane DA transporter (Ritz et al., 1987)), induced
sensitized D2-AR responses, an eﬀect not observed in
VTA DA neurons (Dragicevic et al., 2014). These
sensitized D2-AR responses were isradipine-sensitive in
wildtype, as well as in Cav1.2DHP
/ mice (expressing
Cav1.2 LTCCs insensitive to DHPs (Sinnegger-Brauns
et al., 2004; Striessnig and Koschak, 2008)). These
ﬁndings pinpoint to Cav1.3 LTCCs as crucial players for
this altered inhibitory eﬀect of DA in response to in vivo
transient high-dopamine states. We further demonstrated
that in addition to Cav1.3 LTCC function, calcium-
dependent interaction of NCS-1 with D2-ARs was crucial
for the sensitized, adult-like D2-AR control of SN DA
activity (Dragicevic et al., 2014). NCS-1/D2-R interaction
prevents D2-R desensitization by preventing Gprotein-coupled receptor kinase 2 (GRK2)-mediated
phosphorylation of D2-R and thus b-arrestin-mediated
receptor-internalization (Beaulieu and Gainetdinov,
2011; Kabbani et al., 2012). In summary, LTCCs in
interplay with NCS-1 can adapt SN DA activity to
extracellular DA levels via calcium-dependent modulation
of D2-AR signaling (see Figs. 1 and 2; (Dragicevic et al.,
2014)). In other words, Cav1.3 LTCCs can act as
homeostatic gatekeepers by controlling sensitized
D2-ARs responses, thus reducing SN DA activity associ-
ated DA release in response to elevated extracellular DA
levels (Dragicevic et al., 2014). This may allow them to
control overexcitability and to adapt motor function within
the basal ganglia network. Indeed, we detected elevated
mRNA levels of D2-AR, GIRK2 and NCS-1 in remaining
human SN DA neurons from PD patients, compared to
controls, pointing to a similar signaling network in
humans that might contribute to PD pathology (Fig. 3
and (Dragicevic et al., 2014)).
Contribution of LTCCs in SN DA neurons to PD
pathology
LTCC activity and related calcium signaling however
comes at a high price, since it burdens SN DA neurons
with an oscillatory calcium load, associated with their
electrical activity (Guzman et al., 2010; Surmeier et al.,
2011). In highly vulnerable SN DA neurons, this oscilla-
tory intracellular calcium is only weakly buﬀered due to
the absence or low levels of calcium-binding proteins,
such as calbindin (CBd28k)) ((Hurley et al., 2013;
Yamada et al., 1990; Tan et al., 2000) and compare
Fig. 3). Instead, internal free calcium is taken up by the
ER and mitochondria (Eisner et al., 2013; Hajnoczky
et al., 2014). Mitochondrial calcium uptake is mediated
by calcium transporters (in particular by the mitochondrial
calcium uniporter mCU and by uncoupling proteins, UCPs
(Perocchi et al., 2010; Baughman et al., 2011; De Stefani
et al., 2011; Drago et al., 2011; Waldeck-Weiermair et al.,
2011; Mallilankaraman et al., 2012)). Through activation
of e.g. enzymes of the tricarboxylic acid cycle (TCA),
calcium can increase activity of the electron transfer chain
(ETC) – and thus increase generation of ROS and meta-
bolic stress (McCormack et al., 1990; Sanchez-Padilla
et al., 2014). At higher mitochondrial calcium levels,
calcium also stimulates a mitochondrial nitric oxide
synthase (mNOS), leading to increased nitric oxide (NO)
levels, and possibly inhibition of complex IV of the ETC
(cytochrome oxidase) (Traaseth et al., 2004; Murphy,
2009; Sanchez-Padilla et al., 2014). Thus, in a negative
feedback-loop, higher mitochondrial calcium levels could
slow down the ETC and mitochondrial calcium uptake
(Sanchez-Padilla et al., 2014). However, this feedback
mechanism also stimulates the production of superoxide
anions, which further elevates oxidative stress levels
due to calcium and LTCC function (Cav1.2 and in particu-
lar Cav1.3). This has recently been elegantly shown for
locus coeruleus (LC) neurons, also displaying a high
vulnerability to degeneration in PD (Sanchez-Padilla
et al., 2014). It is very likely that a similar mechanism is
also present in SN DA neurons, thereby contributing to
compromised mitochondrial and bioenergetic function
Fig. 2. Possible network of ion channel functions in SN DA neurons in health and Parkinson’s disease (PD) states. Top: Activity-dependent Ca2+
load due to activity of LTCCs and other VGCC, in interplay with K-ATP/NMDA-R mediated burst activity, and Ca2+ stimulated tricarboxylic acid
cycle and mNOS, creates a high metabolic burden (ROS) for SN DA neurons that is under physiological conditions controlled by several feedback
mechanisms, like ER and mitochondrial Ca2+ buﬀering, mild mitochondrial membrane potential uncoupling (UCP), antioxidative enzymatic
mechanisms (e.g. DJ-1, SOD function), as well as Ca2+ and/or metabolically controlled stimulation of ion channels that reduce SN DA electrical
activity (e.g. D2-AR/NCS-1/GIRK2, K-ATP, SK3, and A-type K+ channels) and Ca2+-dependent gene-expression. Bottom: If metabolic stress
levels (and related levels of Ca2+, ROS and NO) are further elevated (e.g. due to PD-trigger factors, like PD-toxins, PARK-gene mutations, age-
related accumulation of mitochondrial deletions/dysfunction, or altered excitatory synaptic inputs), these control mechanisms might no longer be
suﬃcient, leading to pathophysiologically altered SN DA activity, altered gene-expression, and ﬁnally cell death (for details, see text). Abbreviations:
same as in Fig. 1.
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rendering them more vulnerable to PD-trigger factors
and degeneration.
Consequently, pharmacological inhibition of LTCC
function in SN DA neurons might oﬀer a novel
neuroprotective strategy for PD, potentially inhibiting
complex calcium-signaling and associated mitochondrial
stress in SN DA neurons, and thereby reducing their
high susceptibility to degeneration (Surmeier et al.,
2010). LTCC blockers are already well-established drugs,
and are commonly prescribed to treat hypertension in clin-
ical practice (Epstein et al., 2007; Exner et al., 2012; Coca
et al., 2013). Indeed, retrospective epidemiological
studies demonstrated that systemic administration of
blood–brain-barrier permissive LTCC blockers of the
DHP-type (like isradipine) reduce the relative risk for
developing PD of about 30 % (Becker et al., 2008; Ritz
et al., 2010; Simuni et al., 2010; Marras et al., 2012;
Pasternak et al., 2012; Parkinson Study, 2013). However,
reliable prospective studies are still missing, and not all
epidemiologic studies report PD-protective eﬀects of
LTCC blockers (Ton et al., 2007; Louis et al., 2009;Simon et al., 2010). It is noteworthy, that in all of these
three studies, no stratiﬁcation for exclusive DHP
treatment was made, but data were pooled for both
DHP and non-DHP calcium channel blockers.
In neurotoxic animal models of PD (MPTP, 6-OHDA),
DHP LTCC blockers indeed seem to protect SN DA
neurons from degeneration in mice (Kupsch et al., 1995;
Chan et al., 2007) and non-human primates (Kupsch
et al., 1996) in a dose-dependent manner (Ilijic et al.,
2011), but these ﬁndings need to be conﬁrmed in further
studies. The systemic DHP-plasma levels reached in
mice for SN DA protection seem to be similar to those
described in humans when treated for high blood pres-
sure (2–4 ng/ml in mice and 1–2 ng/ml in humans at
10 mg/day (Surmeier et al., 2011; Surmeier and
Schumacker, 2013)). It is noteworthy that the human
epidemiologic or mouse in vivo studies show a SN DA
protective eﬀect of systemic LTCC-blockers, but they do
not demonstrate that this protective eﬀect is a direct
consequence of inhibiting SN DA LTCCs and related
calcium signaling at these therapeutic plasma levels.
However, work from Surmeier and colleagues provides
Fig. 3. Elevated mRNA-levels of distinct ion channel subunits and Ca2+-binding proteins in human SN DA neurons in Parkinson’s disease. (A)
Individual, human neuromelanin- and tyrosine hydroxylase-positive SN DA neurons were laser-microdissected from human post mortem midbrain
sections of control and PD brains (scale bars = 20 lm, adapted from Schiemann et al., 2012 and Dragicevic et al., 2014), and subjected to reverse
transcription and quantitative PCR (RT-qPCR) analysis as described (Grundemann et al., 2011; Schlaudraﬀ et al., 2014). (B) Cell-speciﬁc RT-qPCR
analysis identiﬁed elevated mRNA-levels of the Ca2+-binding proteins calbindin (CB) and NCS-1, as well as of D2-AR, GIRK2, Kv4.3, SUR1 and the
NMDA-R pore forming subunit NR1 in remaining tyrosine hydroxylase (TH)-positive SN DA neurons from PD patients, compared to those of controls
(Schlaudraﬀ, 2010; Schiemann et al., 2012; Dragicevic et al., 2014). Thus, SN DA-speciﬁc ion channel functions identiﬁed in mice might also be
present in human SN DA neurons and contribute to PD-pathology. For details, see text. Abbreviations: same as in Fig. 1.
804 E. Dragicevic et al. / Neuroscience 284 (2015) 798–814evidence that this might indeed be the underlying
protective mechanism. They have shown that isradipine
(200 nM) reduces oxidative stress levels and mitochondrial
membrane potential ﬂickering, associated with LTCC activ-
ity in SN DA neurons that is elevated in PARK7 (DJ-1)
KO mice (Guzman et al., 2010; Surmeier et al., 2011).
Also, isradipine (1 lM) inhibited calcium-related oxidative
stress levels due to mNOS activity in LC neurons
(Sanchez-Padilla et al., 2014).
Based on these ﬁndings, blood–brain-barrier
permeable LTCC blockers (ideally administered very
early or before PD-symptoms manifest, and most SN
DA neurons are lost) are already in clinical trials as a
novel neuroprotective therapeutic strategy in PD
(ClinicalTrials.gov Identiﬁer: NCT00909545, (Simuni
et al., 2010; Parkinson Study, 2013)). Given the described
complex beneﬁcial, as well as detrimental eﬀects of
LTCCs on calcium signaling pathways in SN DA and other
neurons, unpredictable side eﬀects of chronic pharmaco-
logical LTCC block might occur, however DHPs are
already prescribed long term to many patients to treat
hypertension without signiﬁcant problems. Nevertheless,
neuron-type-, LTCC-isoform- and splice-variant-speciﬁc
(Koschak, 2010; Bock et al., 2011; Hofmann et al.,
2014; Lieb et al., 2014), blood–brain–barrier permeable
blockers, or selective blockers of detrimental calcium
signaling downstream of LTCCs would be required for
tailored PD-preventive therapy. Indeed, novel identiﬁed
Cav1.3 selective LTCC antagonists, pyrimidinetriones
(PYTs), have recently been reported as potential new
therapeutics for PD (Kang et al., 2012; Kang et al.,2013). But it is currently unclear under which conditions
they act as Cav1.3-selective inhibitors or possibly even
activators (Huang et al., 2014; Ortner et al., 2014), and
their PD-protective eﬀect has not yet been demonstrated
in clinical studies.FUNCTIONAL ROLES OF K-ATP CHANNELS IN
SN DA NEURONS
Role of SN DA K-ATP channels for burst activity and
novelty-related behavior
K-ATP channels in SN DA (and VTA DA) neurons in adult
mice and in humans are formed by four pore-forming,
inwardly rectifying Kir6.2 subunits and four regulatory
SUR1 subunits (sulfonylurea receptor, ABC-transporter
superfamily) (Nichols, 2006; Liss & Roeper, 2010).
K-ATP channels have ﬁrst been described in pancreatic
ß-cells, where their closure in response to rising blood
glucose levels – and concomitantly increased intracellular
ATP levels – is triggering insulin secretion (Ashcroft et al.,
1984; Nichols, 2006; Clark and Proks, 2010; Seino,
2012). Moreover, K-ATP channels are active in a variety
of diﬀerent cell types and are ubiquitously expressed
throughout the brain and other tissues (Liss et al., 2005;
Nichols, 2006; Ashcroft, 2007). K-ATP channels are phar-
macologically blocked by sulfonylureas such as glibencla-
mide or tolbutamide (Amoroso et al., 1990; Gomis and
Valdeolmillos, 1998; Kanno et al., 2002; Bryan et al.,
2005; Ashcroft, 2007), and their activity is physiologically
regulated by a variety of metabolic signals, such as
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PIP2, pH, hydrogen peroxide and NO (Spanswick et al.,
2000; Levin et al., 2004; Lin et al., 2004; Avshalumov
et al., 2007; Haider et al., 2007; Andrews et al., 2009;
Leinninger et al., 2009; Opland et al., 2010; Fioramonti
et al., 2011; Levin et al., 2011; Rice, 2011). In essence,
the open probability of K-ATP channels generally
increases in metabolic demand situations, and this
leads to hyperpolarized membrane potentials and
reduced electrical activity (Nichols, 2006; Ashcroft and
Rorsman, 2013). By this mechanism, K-ATP
channels adapt energy-demanding electrical activity of
excitable cells to their metabolic states, and can protect
neurons from overexcitability and excitotoxicity, e.g. in
ischemic preconditioning (Liss and Roeper, 2001;
Yamada and Inagaki, 2005; Soundarapandian et al.,
2007).
For SN DA neurons, we have recently identiﬁed a
novel speciﬁc physiological role of K-ATP channels. In a
subpopulation of medial SN DA neurons, projecting to
the dorsomedial striatum, K-ATP channel activity
facilitates the switch from tonic ﬁring to NMDA
glutamate receptor (NMDA-R)-mediated burst activity
in vivo (Johnson et al., 1992; Johnson and Wu, 2004;
Deister et al., 2009; Zweifel et al., 2009; Schiemann
et al., 2012). More precisely, in adult global Kir6.2
knock-out (KO) mice (Minami et al., 2004), or in adult
WT mice after cell-selective, virus-mediated silencing of
K-ATP channel function, phasic burst ﬁring of medial SN
DA neurons in vivo was decreased about two-fold, without
changes in tonic ﬁring rates (Schiemann et al., 2012). In
the same study, we demonstrated that pharmacological
co-activation of K-ATP channels and NMDA receptors
was suﬃcient to induce burst ﬁring in vitro in medial
SN DA neurons. K-ATP channels could gate
NMDA-R-mediated bursting in SN DA neurons by
providing a hyperpolarizing component as described
(Gomis and Valdeolmillos, 1998; Kanno et al., 2002;
Shen and Johnson, 2010; Schiemann et al., 2012),
necessary for in vitro SN DA burst activation by NMDA
(Johnson et al., 1992; Johnson and Wu, 2004). However,
future studies are required to reveal the detailed
mechanisms underlying K-ATP channel-gated bursting.
Beyond that, we could show that K-ATP channel-
gated burst ﬁring in medial SN DA neurons was
necessary for novelty-induced exploration in vivo. Kir6.2
KO mice, or WT mice after cell-selective silencing of
medial SN DA K-ATP channels, displayed signiﬁcantly
reduced novelty-induced exploratory behavior (da Silva
and Costa, 2012; Schiemann et al., 2012). Consequently,
K-ATP channels in these neurons could integrate multiple
metabolic signals and transduce them into their
open-probability, and thereby tune and adapt in vivo burst
activity and related behavior to distinct metabolic
demands.
In summary, K-ATP channels trigger burst ﬁring in a
subpopulation of medial SN DA neurons, leading to
phasic DA release, and to associated (dopamine D1
receptor-dependent) exploration and goal-directed
behavior in response to novel situations and contextual
changes (Frank et al., 2004; Rutledge et al., 2009;Schiemann et al., 2012). Consistent with these ﬁndings
in rodents, recent human functional brain imaging data
revealed that a corresponding rostromedial part of the
medial SN/VTA midbrain complex in humans is indeed
strongly and selectively activated by novel, but
non-rewarding stimuli (Krebs et al., 2011). These ﬁndings
indicate that K-ATP channels in human SN DA neurons
may have a similar role for promoting burst activity and
novelty-related behavior.K-ATP channels as metabolic gatekeepers: SN DA
activity control in response to metabolic stress
As described, K-ATP channels integrate and transduce a
variety of metabolic signals into their speciﬁc open
probability. Thus, these channels act as metabolic
gatekeepers, adapting SN DA activity to the metabolic
state of these cells (or the organism) based on two
diﬀerent strategies: I) in context of the above described
K-ATP channel-mediated burst facilitation in SN DA
neurons, metabolic demand situations would increase
the open probability of K-ATP channels and thus
enhance burst activity of SN DA neurons as well as
exploratory behavior (e.g. to ﬁnd novel food sources). II)
if K-ATP channel activity is further increased in SN DA
neurons, e.g. due to enhanced oxidative mitochondrial
stress, mitochondrial dysfunction, elevated calcium
levels or PD-toxins (like MPTP or rotenone), the
resulting membrane potential hyperpolarization will at
some point inevitably lead to reduced activity, or even
silencing of the cell, as we demonstrated in vitro in adult
mice (Liss et al., 2005). Reduced SN DA activity would
be beneﬁcial in metabolic stress situation in the short
run, as it reduces metabolically demanding burst ﬁring,
as well as the activity of the highly ATP consuming
N+/K+ ATPase, which is stimulated by electrical activity
(Johnson et al., 1992). However in the long run, reduced
electrical activity could be detrimental for SN DA neurons,
as detailed below. In this context, it is important to note
that even though both, SN DA as well as VTA DA neurons
express functional K-ATP channels of the same molecu-
lar make-up (Kir6.2/SUR1), their metabolic sensitivity
and thus open probability is intrinsically higher in vulnera-
ble SN DA neurons due to a lower degree of physiological
mitochondrial uncoupling (lower expression of the
uncoupling protein UCP2) (Liss et al., 2005). Indeed, mild
pharmacological mitochondrial uncoupling or superoxide-
dismutase mimetics can reduce generation of ROS and
reduce K-ATP channel open probability, without
compromising ATP production in SN DA neurons (Liss
et al., 2005).Contribution of K-ATP channels in SN DA neurons to
PD pathology
K-ATP channels in highly vulnerable SN DA neurons are
particularly sensitive to metabolic stress, caused in
animal models e.g. by PD-trigger factors such as the
mitochondrial complex I blockers MPTP or rotenone
(Liss et al., 2005). The resulting increased activity of
K-ATP channels due to pathophysiological metabolic stress
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SN DA activity (Liss et al., 2005). This adaptive response
might be beneﬁcial in acute scenarios as described.
However, chronic pathophysiological activation of K-ATP
channels in SN DA neurons in response to chronic in vivo
PD-toxins has been shown not to be beneﬁcial but to trigger
their selective degeneration (Liss et al., 2005). More
precisely, genetic inactivation of K-ATP channels in global
Kir6.2 KO mice resulted in a selective and complete rescue
of adult SN DA neurons in a chronic low-dose in vivo
MPTP PD-model (Liss et al., 2005; Meredith and
Rademacher, 2011). Moreover, loss of K-ATP channels
induced a similar selective rescue of highly vulnerable SN
DA (but not VTA DA) neurons in a mechanistically diﬀerent,
genetic model of selective SN DA degeneration, the
weaver mouse (Girk2wv/wv) (Liss et al., 2005). In cell
culture, the K-ATP channel blocker glibenclamide
(30–100 lM) protected DA neurons in juvenile rats (PN15)
from PD-triggers and degeneration – presumably via
disrupting their mitochondrial calcium homeostasis
(Toulorge et al., 2010).
In addition, our data for human SN DA neurons further
point to a role of K-ATP channels for PD pathology: we
found that remaining SN DA neurons from PD patients
compared to those of controls express about twofold
higher levels of the K-ATP channel subunit SUR1,
responsible for channel traﬃcking to the plasma
membrane (Tucker et al., 1997; Sharma et al., 1999),
as well as about 10-fold higher levels of the NMDA-R pore
forming subunit NR1 (compare Fig. 3 and (Schiemann
et al., 2012)). In accordance with the described K-ATP
NMDA-R interplay for triggering burst ﬁring in mouse SN
DA neurons, human SN DA neurons of PD patients seem
to display high levels of bursting, as recorded in awake
patients during DBS (Zaghloul et al., 2009; Schiemann
et al., 2012) – possibly as a compensatory response to
the progressive loss of SN DA neurons. Moreover,
reduced novelty seeking, as well as reduced exploratory
excitability have been documented for PD patients (Bodi
et al., 2009; Rutledge et al., 2009). However, high levels
of metabolically demanding (compensatory) burst activity
will also further increase metabolic stress in these
neurons, as described.
Taken together, these rodent and human data
suggest that pharmacological blockade of K-ATP
channels in SN DA neurons might provide another novel
neuroprotective strategy for PD. Pharmacological K-ATP
channel blockers (like glibenclamide) are – similar to
LTCC blockers – already well-established and widely
used drugs to treat type 2 diabetes (T2D) (Ashcroft,
2007; Ashcroft and Rorsman, 2013). And there is evi-
dence for a certain blood–brain barrier penetrance of
these drugs (Ashcroft, 2010). Indeed, retrospective
meta-analyses revealed epidemiological evidence of a
reduced risk for PD in T2D patients treated with K-ATP
channel blockers (Powers et al., 2006; Scigliano et al.,
2006; Schernhammer et al., 2011; Wahlqvist et al.,
2012; Cereda et al., 2013; Lu et al., 2014). However, sta-
tistical analysis is complicated by the fact that T2D per se
seems to increase the risk for PD (Hu et al., 2007; Lima
et al., 2014; Zhang and Tian, 2014), and there is evidencethat T2D and PD might share similar disease pathways
(Santiago and Potashkin, 2013). To our knowledge,
K-ATP channel blockers are currently not systematically
tested as a novel neuroprotective strategy in PD. And
similarly as for LTCCs blockers, given the widespread
functional expression of K-ATP channels, SN DA and
K-ATP subtype-speciﬁc drugs would be desired.
However, the NMDA-R antagonist memantine is in trial
for PD therapy and seems to be beneﬁcial (Emre et al.,
2010). Interestingly, memantine also acts as a K-ATP
channel blocker, and aﬀect SN DA burst ﬁring, indepen-
dently of NMDA-R function (Giustizieri et al., 2007).COMPLEX ION CHANNEL INTERPLAY IN SN DA
NEURONS IN HEALTH AND PD: POSSIBLE
MECHANISMS AND THERAPEUTICAL
IMPLICATIONS
In essence, Cav1.3 LTCCs with low voltage-activation as
well as K-ATP channels with high metabolic sensitivity
render SN DA neurons particularly vulnerable to
PD-triggers and degeneration, as described. However,
the question remains, why do SN DA neurons need these
two channels that generate a high metabolic burden,
while VTA DA neurons function well without depending on
them? The answer is still not clear. However, here we
summarize ﬁndings and oﬀer our views and hypotheses
(Fig. 2, Fig. 3) for the speciﬁc physiological roles of LTCC
and K-ATP channels in SN DA neurons, as well as for the
possible pathophysiological consequences of their related
activity in response to PD-trigger factors.
We showed that K-ATP channel function (in interplay
with NMDA-R), is crucial for triggering phasic burst
activity in SN DA neurons as well as novelty-related
explorative behavior of mice (Schiemann et al., 2012).
This mechanism will likely, in metabolic demand situa-
tions (e.g. low blood glucose levels, hunger, or food depri-
vation), stimulate motor activity and exploration,
increasing the chance to locate novel food sources. As
a consequence, enhanced stressful burst ﬁring and
related NMDA-R activity will however further increase cal-
cium load, related mitochondrial stress, and ROS, as well
as activity-related metabolic stress as previously
described (e.g. due to augmented N+/K+ ATPase activity
in SN DA neurons). On the other hand, increased meta-
bolic stress will further activate K-ATP channels in SN
DA neurons, and thus hyperpolarize the cell, thereby
providing an intrinsic control mechanism, which could
prevent overexcitability and related excitotoxicity.
We propose a similar complex functional role of
Cav1.3 LTCCs in SN DA neurons, as these channels
are not crucial for generating spontaneous activity of
these neurons. We hypothesize that the pulsatile
calcium signals, caused by Cav1.3 channels during
spontaneous activity, are essential for other
physiological functions speciﬁcally of SN DA neurons
(Mosharov et al., 2009). On one hand, LTCC-mediated
calcium inﬂux will directly activate calcium dependent
enzymes, like e.g. those of the TCA (Plaitakis and
Shashidharan, 2000; Carafoli, 2010) and mNOS
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LTCC-mediated calcium inﬂux will stimulate or repress
gene expression, selectively in SN DA neurons, via direct
or indirect calcium-dependent modulation of gene
transcription (West et al., 2001), e.g. via CREB (cAMP
response element-binding protein) and DREAM (DRE
antagonist modulator) pathways (Mandel and Goodman,
1999; Osawa et al., 2001; Screaton et al., 2004; Rivas
et al., 2011; Zhang et al., 2011; Selvakumar et al.,
2014). Similar as K-ATP-mediated burst activity, this
physiological LTCC-function creates however, a high
metabolic burden for SN DA neurons. Consequently,
intrinsic negative feedback control mechanisms are again
present to prevent LTCC-mediated overexcitability and
excitotoxicity: elevated internal calcium levels lead to
enhanced NCS-1-mediated sensitization of D2-AR func-
tion in SN DA neurons, and thus increased GIRK2 K+
channel-mediated hyperpolarization and DA autoinhibi-
tion of electrical activity (Dragicevic et al., 2014).
An additional calcium-sensitive feedback mechanism
could be provided by calcium and voltage-sensitive
A-type K+ channels (Jerng and Pfaﬃnger, 2014). In SN
DA neurons, these channels are built by Kv4.3 pore-form-
ing subunits and regulatory calcium-sensing KChip3 sub-
units (Liss et al., 2001), also members of the NCS-1
family (Figs. 1–3; (An et al., 2000; Jerng and Pfaﬃnger,
2014; Turner and Zamponi, 2014)). A-type K+ channels
inhibit pacemaker activity of SN DA but not of VTA DA
neurons by prolonging the interspike interval (Liss et al.,
2001; Liss and Roeper, 2002; Lammel, 2004) with
increased inhibitory eﬀects with elevated levels of free
intracellular calcium (Jerng and Pfaﬃnger, 2014). KChip3,
also known as the calcium-dependent transcriptional
repressor DREAM (Jo et al., 2001; Buxbaum, 2004),
surprisingly does not only act as a calcium-sensing
regulatory subunit of A-type K+ channels, but e.g. can
also – dependent on free intracellular calcium levels –
shuttle to the nucleus and regulate gene expression
(Li and Adelman, 2000; Sours-Brothers et al., 2009;
Mellstrom et al., 2014). These multiple functions of
KChip3 allow complex short-term and long-term adap-
tions of electrical activity of SN DA neurons to distinct
calcium levels and homeostatic needs. Thus, calcium
dependent A-type K+ channel activity could also counter-
act LTCC as well as K-ATP/NMDA-R-mediated overexcit-
ability and excitotoxicity. As a further control mechanism,
KChip3/DREAM could reduce K-ATP/NMDA-R-mediated
burst activity by negatively modulating NMDA-R activity
(Wang and Wang, 2012). Activation of DREAM also
reduces L-DOPA-induced dyskinesias in mice (Ruiz-
DeDiego et al., 2014). Consequently, pharmacological
modulation of A-type K+ channels in SN DA neurons
might provide another neuroprotective strategy for PD.
Indeed, cell-speciﬁc data from our group show a dramatic
increase of A-type K+ channel pore-forming Kv4.3 mRNA
in surviving human SN DA neurons from end stage PD
patients, compared to controls (see Fig. 3), supporting
this view of a protective A-type channel function in
vulnerable SN DA neurons.
In summary, LTCC and K-ATP channel function in SN
DA neurons are crucial for their speciﬁc physiologicalfunction, but they generate an activity-related metabolic
burden for those neurons (Ca2+, ROS and NO levels)
that renders them particularly vulnerable to PD-triggers
and degeneration. Consequently, as summarized in
Fig. 2A, a variety of backup mechanisms are present in
SN DA neurons to control and counteract LTCC and
K-ATP channel-triggered overexcitability and excitotoxicity
(D2-AR/GIRK2, SK3, A-type K+ channels, K-ATP
channels), or to counteract Ca2+, metabolic stress and
ROS (e.g. SOD, UCPs, DJ-1/PARK7, (Guzman et al.,
2010; Surmeier et al., 2012)). Under physiological
conditions, this complex network of activity-controlling ion
channels and metabolic protection pathways, in interplay
with ER and mitochondrial Ca2+ buﬀering, allows LTCC
and K-ATP channel function in SN DA neurons without
triggering degenerative pathways (Fig. 2A).
However, what happens if PD-triggers further
contribute to this intrinsic metabolic stress of SN DA
neurons? These triggers could be intrinsic PARK-gene
mutations (such as DJ-1), or increased age and age-
related mitochondrial dysfunction, or extrinsic factors,
such as environmental toxins (e.g. rotenone MPTP), or
PD-related alterations in glutamatergic synaptic input
(Rodriguez et al., 1998; Hardy, 2010; Meredith and
Rademacher, 2011).
As illustrated in Fig. 2B, all these PD-triggers can
synergistically increase mitochondrial dysfunction, general
metabolic stress and intracellular free calcium load,
ROS and NO levels. At this point, a vicious circle could
take its course, by further stimulating mNOS/NO-levels,
and thus not only possibly reduce ETC activity
(Sanchez-Padilla et al., 2014), but also elevate superox-
ide levels, further increasing mitochondrial stress, as
described above (Surmeier et al., 2010; Sanchez-Padilla
et al., 2014). NO itself as well as ROS / mitochondrial
dysfunction will further increase the open probability of
K-ATP channels (Zhang et al., 2001; Lin et al., 2004),
which – until a certain point – will stimulate stressful burst-
ing of SN DA neurons, and thus further drive the vicious
cycle of Ca2+ load, metabolic stress and excitotoxicity
that can no longer be properly controlled by the described
inhibitory feedback mechanisms. On the other hand,
in a chronic interplay of increased Ca2+-dependent
D2/GIRK2 and A-type K+ channel activity, further
K-ATP channel activation would rather lead to a chronic
reduction of SN DA activity, as described above, and thus
likely lead to a reduction of activity-dependent vital
factors, like brain-derived neurotrophic factor (BDNF)
(Hyman et al., 1991; Kurauchi et al., 2011; Peng et al.,
2011). In either scenario, the inhibitory feedback systems
in SN DA neurons, likely serving to protect from metabol-
ically precarious physiological LTCC and K-ATP activity
and related pathophysiological overexcitability, would
eventually fail in the chronic presence of too high levels
of metabolic stressors in PD, ultimately leading to the
selective death of SN DA neurons.CONCLUSIONS
The pathological hallmark of PD, which causes the major
motor-related symptoms of the disease, is the selective
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evidence that physiological LTCC (in particular of the
Cav1.3 type) as well as K-ATP channel (made up by
Kir6.2/SUR1 subunits) function contribute to metabolic
stress and the selective high vulnerability of SN DA
neurons to degeneration in PD and its animal models.
Nevertheless, these channels in SN DA (but not in VTA
DA) neurons seem to be crucial for their distinct
electrical activity patterns, their physiological signaling
(e.g. calcium-dependent enzyme activation and
regulation of gene expression), and their related
complex functions within the basal ganglia network (e.g.
novelty-related behavior). However, physiological K-ATP
and LTCC activity generates an intrinsic high metabolic
burden for SN DA neurons, due to associated burst
activity and activity-dependent elevated intracellular
Ca2+ levels. We hypothesize that consequently, a
complex network of inhibitory feedback mechanisms is
present in SN DA neurons to control physiological
LTCC and K-ATP channel function and to
homeostatically tune SN DA activity pattern to the
metabolic states of these neurons, to thus circumvent
overexcitability and excitotoxicity. Ca2+-dependent
sensitization of inhibitory D2-AR/GIRK2 signaling as well
as Ca2+-dependent A-type K+ channel signaling in SN
DA neurons provide just two distinct potential feedback
mechanisms.
However, activity patterns of SN DA neurons are
controlled by a variety of additional ion channels and
receptors (compare Fig. 1), and thus this network is
even more complex than described here. To further
illustrate the complexity, recent evidence shows
functional coupling of voltage-gated T-type Ca2+
channels with A-type K+ channels (Kv4.3) via Ca
2+
levels and KChip3 (Anderson et al., 2010; Turner and
Zamponi, 2014), and we gained evidence for an interplay
of TTCCs with LTCCs and K-ATPs. Not only in this con-
text, it is very important to systematically study the cell-
speciﬁc contributions of other voltage-gated calcium
channels (like P-, N-, Q-, R-, and T-type channels
(Catterall et al., 2005)) to SN DA function in health and
PD. In view of desired novel neuroprotective PD-thera-
pies, these ion channels provide promising potential tar-
gets, in addition to LTCC-blockers, which are already in
clinical trials (Parkinson Study, 2013). However, as all
these channels are not only expressed in SN DA neurons,
but in a variety of other neuronal and non-neuronal cells,
the development of channel subtype-speciﬁc blockers
that ideally selectively target SN DA neurons, is desired.
Future research is needed to develop those blockers,
and to address acute and chronic pathophysiological con-
sequences, as well as side eﬀects of pharmacological
modulation of the emerging complex network of ion
channel functions in SN DA neurons, as potential novel
therapeutic strategies in PD.FUNDING
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